Cost-Utility Analysis of Simeprevir With Peginterferon + Ribavirin (SMV/PR) in the Management of Genotype 1 (G1) and 4 (G4) Hepatitis C Virus (HCV) Infection; from the Perspective of the Uk National Health Service (NHS).

Value Health

JB Medical Ltd, Sudbury, UK.

Published: November 2014

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jval.2014.08.2527	DOI Listing

Publication Analysis

cost-utility analysis

analysis simeprevir

simeprevir peginterferon

peginterferon ribavirin

ribavirin smv/pr

smv/pr management

management genotype

genotype hepatitis

hepatitis virus

virus hcv

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!